Journal
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Volume -, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/10781552211067429
Keywords
nivolumab; non-small cell lung cancer; imnune-related adverse events
Categories
Ask authors/readers for more resources
This study focused on immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients treated with nivolumab. The results showed that patients who developed irAEs had longer progression free survival (PFS) and overall survival (OS) compared to those without irAEs, with statistically significant differences. Furthermore, patients who experienced two or more irAEs derived the greatest benefit in terms of treatment effectiveness.
Objective: To study immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients treated with nivolumab, as well as to assess whether these reactions could be predictors of further effectiveness of therapy. Methods: Retrospective, observational and longitudinal study. All NSCLC patients who received nivolumab between February 2015-May 2020 were included. In terms of safety, irAEs and their severity were registered and to evaluate the effectiveness, overall survival (OS) and progression free survival (PFS) were calculated. Results: 75 patients were included. 32 patients (43%) were reported irAES. Mainly the irAEs affected the skin (36%). Followed by pneumonitis (20%), gastrointestinal reactions (12%), endocrine (12%) and hepatitis (12%). Regarding severity, 92% were moderate. The median PFS was 9.49 months on the group with irAEs versus 1.99 months on the group without irAEs group (p < 0.0001). The median OS was 17.44 months versus 7.67 months respectively (p = 0.0001). According to the incidence of irAEs developed ( = > 2 vs. 1 vs. 0), the median PFS was 20.53 versus 5.35 versus 1.99 months respectively (p < 0.0001). The median OS was 23.41 versus 15.80 versus 7.67 months, respectively (p = 0.0002) Conclusion: In a significant number of patients irAEs occur, generally of grade 1-2 severity, affecting mainly the skin, lungs and gastrointestinal system. We confirm that the development of irAEs in patients with NSCLC treated with nivolumab is a strong predictor of treatment effectiveness in both PFS and OS, with statistically significant results. On those patients who experience two or more immunorelated adverse events the greatest benefit has been observed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available